Recommendations for the reduction of compound artifacts in time-resolved fluorescence resonance energy transfer assays

Assay and Drug Development Technologies

Volumn 5, Issue 3, 2007, Pages 363-372

  Imbert, Pierre Eloi ^a   Unterreiner, Vincent ^a   Siebert, Daniela ^a   Gubler, Hanspeter ^a   Parker, Christian ^a   Gabriel, Daniela ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; ARTIFACT; AUTOFLUORESCENCE; CONTROLLED STUDY; EXCITATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; KINETICS; NONHUMAN; REACTION TIME;

ARTIFACTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FLUORESCENCE RESONANCE ENERGY TRANSFER; TIME FACTORS;

EID: 34447498924     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2007.073     Document Type: Article

References (15)

1. Mathis G: Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin Chem 1993;39: 1953-1959.
2. Bazin H, Preaudat M, Trinquet E, Mathis G: Homogeneous time resolved fluorescence resonance energy transfer using rare earth cryptates as a tool for probing molecular interactions in biology. Spectrochim Acta A Mol Biomol Spectrosc 2001;57:2197-2211.
3. Mathis G: Probing molecular interactions with homogenous techniques based on rare earth cryptates and fluorescence energy transfer. Clin Chem 1995;41:1391-1397.
4. Gabriel D, Vernier M, Pfeifer MJ, Dasen B, Tenaillon L, Bouhelal R: High throughput screening technologies for direct cyclic AMP measurement. Assay Drug Dev Technol 2003;1:291-303.
5. Kuerner JM, Klimant I, Krause C, Pringsheim E, Wolfbeis OS: A new type of phosphorescent nanospheres for use in advanced time-resolved multiplexed bioassays. Anal Biochem 2001;297:32-41.
6. Clapp AR, Medintz IL, Uyeda HT, Fischer BR, Goldman ER, Bawendi MG, et al.: Quantum dot-based multiplexed fluorescence resonance energy transfer. J Am Chem Soc 2006;127:18212-18221.
7. Mellor W, Burden N, Preaudat M, Joseph Y, Cooksley S, Ellis J, et al.: Development of a CD28/CD86 (B7-2) binding assay for high throughput screening by homogenous time-resolved fluorescence. J Biomol Screen 1998;3: 91-99.
8. Kolb A, Kaplita P, Hayes D, Park Y, Pernell C, Major J, et al.: Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence. Drug Discov Today 1998;3: 333-342.
9. Clarke E, Shearman M: Quantitation of amyloid-β peptides in biological milieu using a novel homogeneous time-resolved fluorescence (HTRF) assay. J Neurosci Methods 2000;102:61-68.
10. Kane S, Fleener C, Zhang Y, Lenora J, Musselman A, Huang P: Development of a binding assay for p53/HDM2 by using homogeneous time-resolved fluorescence. Anal Biochem 2000;278:29-38.
11. rd, Parakh S, Parker CN, Tripp BC: Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds. J Biomol Screen 2006;11:782-791.
12. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4: 67-73.
13. Macarron R, Hertzberg RP: Design and implementation of high throughput screening assays. Methods Mol Biol 2002;190:1-29.
14. Vogel KW, Vedvik KL: Improving lanthanide-based resonance energy transfer detection by increasing donor-acceptor distances. J Biomol Screen 2006;11:439-443.
15. Sills MA, Weiss D, Pham Q, Schweitzer R, Wu X, Wu JJ: Comparion of assay technologies for a tyrosine kinase assay generates different results in high throughput screening. J Biomol Screen 2002;7:191-214.